Fisher Juliya, Patel Mital, Miller Michael, Burris Katy
Department of Dermatology, SUNY Downstate Medical Center, Brooklyn, New York, USA.
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Cutis. 2016 Aug;98(2):E22-6.
Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) has been associated with numerous drugs, but there are limited reports of its association with aromatase inhibitor anastrozole. We report the case of a patient undergoing treatment with anastrozole for breast cancer who presented with clinical, serological, and histological evidence consistent with DI-SCLE. Her condition quickly began to improve after the use of anastrozole was discontinued and hydroxychloroquine therapy was initiated. Cases such as ours as well as several others that implicate antiestrogen drugs in association with DI-SCLE seem to be contradictory to studies looking at the usefulness of treating systemic lupus erythematosus (SLE) with antiestrogen therapy. Further research on this relationship is warranted.
药物性亚急性皮肤型红斑狼疮（DI-SCLE）与多种药物有关，但关于其与芳香化酶抑制剂阿那曲唑关联的报道有限。我们报告了一例正在接受阿那曲唑治疗乳腺癌的患者，该患者出现了符合DI-SCLE的临床、血清学和组织学证据。在停用阿那曲唑并开始使用羟氯喹治疗后，她的病情迅速开始改善。像我们这样以及其他几例将抗雌激素药物与DI-SCLE相关联的病例，似乎与研究抗雌激素疗法治疗系统性红斑狼疮（SLE）的有效性的研究相矛盾。有必要对这种关系进行进一步研究。
